IL227747A0 - Combinations comprising macitentan for the treatment of glioblastoma multiforme - Google Patents
Combinations comprising macitentan for the treatment of glioblastoma multiformeInfo
- Publication number
- IL227747A0 IL227747A0 IL227747A IL22774713A IL227747A0 IL 227747 A0 IL227747 A0 IL 227747A0 IL 227747 A IL227747 A IL 227747A IL 22774713 A IL22774713 A IL 22774713A IL 227747 A0 IL227747 A0 IL 227747A0
- Authority
- IL
- Israel
- Prior art keywords
- mesitantan
- treatment
- glioblastoma multiforme
- combinations containing
- combinations
- Prior art date
Links
- 201000010915 Glioblastoma multiforme Diseases 0.000 title 1
- 208000005017 glioblastoma Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2011050494 | 2011-02-04 | ||
| PCT/IB2012/050513 WO2012104822A1 (en) | 2011-02-04 | 2012-02-03 | Combinations comprising macitentan for the treatment of glioblastoma multiforme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL227747A0 true IL227747A0 (en) | 2013-09-30 |
Family
ID=45787254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL227747A IL227747A0 (en) | 2011-02-04 | 2013-08-01 | Combinations comprising macitentan for the treatment of glioblastoma multiforme |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20130310407A1 (enExample) |
| EP (2) | EP2965757A1 (enExample) |
| JP (2) | JP5642892B2 (enExample) |
| KR (1) | KR101563069B1 (enExample) |
| CN (1) | CN103327975A (enExample) |
| AR (1) | AR085132A1 (enExample) |
| AU (1) | AU2012213036A1 (enExample) |
| BR (1) | BR112013019680A2 (enExample) |
| CA (1) | CA2823994A1 (enExample) |
| CL (1) | CL2013002193A1 (enExample) |
| CO (1) | CO6761366A2 (enExample) |
| EA (1) | EA201391131A1 (enExample) |
| IL (1) | IL227747A0 (enExample) |
| MA (1) | MA34952B1 (enExample) |
| MX (1) | MX2013008798A (enExample) |
| PH (1) | PH12013501461A1 (enExample) |
| SG (1) | SG192600A1 (enExample) |
| TN (1) | TN2013000333A1 (enExample) |
| TW (1) | TW201309298A (enExample) |
| WO (1) | WO2012104822A1 (enExample) |
| ZA (1) | ZA201306613B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2292209A3 (en) | 2005-09-12 | 2011-05-04 | Actelion Pharmaceuticals Ltd. | Stable pharmaceutical composition comprising a pyramidine-sulfamide |
| PL2464218T3 (pl) | 2009-08-10 | 2015-12-31 | Univ Texas | Leczenie przerzutów do mózgu z zastosowaniem inhibitorów receptorów endoteliny w skojarzeniu z cytotoksycznym środkiem chemioterapeutycznym |
| CN103397308A (zh) * | 2013-08-01 | 2013-11-20 | 光垒光电科技（上海）有限公司 | 用于mocvd设备的喷淋头 |
| TWI559928B (en) * | 2014-08-20 | 2016-12-01 | Academia Sinica | Methods for enhancing permeability to blood-brain barrier and uses thereof |
| KR101701619B1 (ko) | 2015-06-26 | 2017-02-01 | 건양대학교산학협력단 | 뇌교종 세포 치료를 위한 테모졸로마이드와 비타민 d가 포함된 조성물 |
| KR102574253B1 (ko) | 2020-12-15 | 2023-09-07 | 주식회사 시선테라퓨틱스 | 펩티드 핵산 복합체를 유효성분으로 함유하는 교모세포종 예방 또는 치료용 조성물 |
| CN115317604B (zh) * | 2022-08-11 | 2023-09-22 | 南京脑科医院 | 一种靶向胶质瘤的共载放疗增敏阳离子纳米制剂及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU229403B1 (en) * | 2000-12-18 | 2013-12-30 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists |
| EP2292209A3 (en) | 2005-09-12 | 2011-05-04 | Actelion Pharmaceuticals Ltd. | Stable pharmaceutical composition comprising a pyramidine-sulfamide |
| WO2008111092A1 (en) * | 2007-03-09 | 2008-09-18 | Fresenius Kabi Oncology Limited | Crystalline temozolomide monohydrate and process for preparation thereof |
| PL2254570T3 (pl) * | 2008-02-20 | 2014-05-30 | Actelion Pharmaceuticals Ltd | Połączenie zawierające paklitaksel do leczenia raka jajnika |
| PL2464218T3 (pl) * | 2009-08-10 | 2015-12-31 | Univ Texas | Leczenie przerzutów do mózgu z zastosowaniem inhibitorów receptorów endoteliny w skojarzeniu z cytotoksycznym środkiem chemioterapeutycznym |
-
2012
- 2012-02-03 JP JP2013552318A patent/JP5642892B2/ja not_active Expired - Fee Related
- 2012-02-03 MX MX2013008798A patent/MX2013008798A/es active IP Right Grant
- 2012-02-03 PH PH1/2013/501461A patent/PH12013501461A1/en unknown
- 2012-02-03 MA MA36217A patent/MA34952B1/fr unknown
- 2012-02-03 US US13/983,383 patent/US20130310407A1/en not_active Abandoned
- 2012-02-03 TW TW101103560A patent/TW201309298A/zh unknown
- 2012-02-03 EP EP15178064.0A patent/EP2965757A1/en not_active Withdrawn
- 2012-02-03 SG SG2013058979A patent/SG192600A1/en unknown
- 2012-02-03 BR BR112013019680A patent/BR112013019680A2/pt not_active IP Right Cessation
- 2012-02-03 EA EA201391131A patent/EA201391131A1/ru unknown
- 2012-02-03 KR KR1020137023170A patent/KR101563069B1/ko not_active Expired - Fee Related
- 2012-02-03 WO PCT/IB2012/050513 patent/WO2012104822A1/en not_active Ceased
- 2012-02-03 AU AU2012213036A patent/AU2012213036A1/en not_active Abandoned
- 2012-02-03 EP EP12706925.0A patent/EP2670405B1/en not_active Not-in-force
- 2012-02-03 AR ARP120100357A patent/AR085132A1/es unknown
- 2012-02-03 CA CA2823994A patent/CA2823994A1/en not_active Abandoned
- 2012-02-03 CN CN2012800059659A patent/CN103327975A/zh active Pending
-
2013
- 2013-07-10 CO CO13163973A patent/CO6761366A2/es not_active Application Discontinuation
- 2013-07-31 CL CL2013002193A patent/CL2013002193A1/es unknown
- 2013-08-01 IL IL227747A patent/IL227747A0/en unknown
- 2013-08-01 TN TNP2013000333A patent/TN2013000333A1/fr unknown
- 2013-09-03 ZA ZA2013/06613A patent/ZA201306613B/en unknown
-
2014
- 2014-10-28 JP JP2014219218A patent/JP2015057409A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2013002193A1 (es) | 2014-05-09 |
| CN103327975A (zh) | 2013-09-25 |
| CA2823994A1 (en) | 2012-08-09 |
| KR20130118981A (ko) | 2013-10-30 |
| EP2670405A1 (en) | 2013-12-11 |
| JP2015057409A (ja) | 2015-03-26 |
| JP5642892B2 (ja) | 2014-12-17 |
| JP2014504636A (ja) | 2014-02-24 |
| AU2012213036A1 (en) | 2013-09-19 |
| AR085132A1 (es) | 2013-09-11 |
| TW201309298A (zh) | 2013-03-01 |
| EA201391131A1 (ru) | 2013-12-30 |
| MX2013008798A (es) | 2013-10-17 |
| NZ615005A (en) | 2015-10-30 |
| ZA201306613B (en) | 2015-04-29 |
| CO6761366A2 (es) | 2013-09-30 |
| SG192600A1 (en) | 2013-09-30 |
| EP2670405B1 (en) | 2015-09-02 |
| BR112013019680A2 (pt) | 2016-10-11 |
| KR101563069B1 (ko) | 2015-10-23 |
| WO2012104822A1 (en) | 2012-08-09 |
| PH12013501461A1 (en) | 2019-03-22 |
| MA34952B1 (fr) | 2014-03-01 |
| TN2013000333A1 (en) | 2015-01-20 |
| EP2965757A1 (en) | 2016-01-13 |
| US20130310407A1 (en) | 2013-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2020510I1 (lt) | Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui | |
| EP2663304A4 (en) | COMBINATION THERAPY | |
| PL2544682T3 (pl) | Fitokannabinoidy w leczeniu glejaka | |
| BR112013032887A2 (pt) | cateter | |
| EP4144845C0 (en) | ANTISENSE COMPOUNDS AND THEIR USES | |
| IL230657A0 (en) | Compounds for the treatment of addiction | |
| EP2692380A4 (en) | SYRINGE | |
| HUE043171T2 (hu) | Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek | |
| LT2707030T (lt) | Vėžio gydymas | |
| IL231351A0 (en) | Amino-substituted imidazopyridazines | |
| HUE046667T2 (hu) | Rák kombinatív kezelése | |
| EP2726095A4 (en) | COMBINATION THERAPY | |
| DK2760886T3 (da) | Immunocytokin-kombinationsterapi | |
| FI20115876A0 (fi) | Yhdistelmähoito | |
| IL231092A0 (en) | Treatment of rhinitis | |
| DK2489413T5 (da) | Behandlingsapparat | |
| EP2783256A4 (en) | Therapeutic eyewear | |
| EP2769718A4 (en) | MEDICAL COMPOSITION | |
| IL227747A0 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| IL229081A0 (en) | Isoxazolines as therapeutic agents | |
| LT2812013T (lt) | Kompozicija, skirta džs gydymui | |
| BR112013023539A2 (pt) | derivados de isoxazolidina | |
| CO6880064A2 (es) | Métodos terapéuticos | |
| FI20115640A0 (fi) | Yhdistelmähoito | |
| ITRM20120473A1 (it) | Use of glycerophosphoinositols for the treatment of septic shock |